Dr. Francesco Bonella is Head of the Outpatients Clinic for Interstitial and Rare Lung Disease and Assistant Professor at the Ruhrlandklinik University Hospital, Essen, Germany. After receiving his MD and Board Certification at the University of Verona, Italy, he earned his international PhD in Interstitial Lung Diseases at the University of Essen under the guidance of Professor Ulrich Costabel. Dr Bonella’s research interests include IPF, alveolar proteinosis, rheumatic-associated ILDs, and sarcoidosis with a special focus on biomarkers, genetic predisposition and applications of bronchoalveolar lavage. In recent years, he has acted as an investigator for major clinical trials in IPF, sarcoidosis and alveolar proteinosis. He is reviewer for numerous scientific journals and has authored many chapters in textbooks, original articles, case reports, editorials and reviews. He co-founded EuPAPNet, the European Network for Alveolar Proteinosis, and the European Reference Network (ERN)-Lung, leading the ILD core network. He is a member of several scientific societies, was Secretary (now Chair elected) of the ERS DPLD group from 2014 to 2017.
Dr. Yoshikazu Inoue, is an Executive Director, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center (Osaka, Japan), and an Invited Professor of Infection, Immunology and Oncology Cooperating Course, Graduate School, Osaka University (Osaka, Japan). He studied granulomatous lung diseases in his graduate school, and mucin-like glycoproteins when he was an Assistant Professor in Ehime University. From 1994, he had studied granulomatous lung diseases and pulmonary fibrosis in National Jewish Center for Immunology and Respiratory Medicine (Denver, CO, USA). In 1997, he moved to the current institute (Osaka, Japan). His institute is one of the leading hospitals and research centers for chest diseases, and an important referral center for ILDs in Japan. Their team is doing wonderful practice, domestic and international multicenter trials, and clinical/basic researches. He is a member of Japan Society of Sarcoidosis and Other Granulomatous Disorders (JSSOG), Japanese Respiratory Society, Asian Pacific Society of Fleischner Society, Respirology (APSR), ATS, ERS, WASOG, and more. He has been serving as board members, executive committee, Secretary, and Trustee of the societies. He is a WASOG Executive Committee Member from 2011. He is involved in several international guidelines, global clinical trials of PAP, LAM, IIPs, IPF, etc.
He is also helping patient’s societies/foundations as Medical Advisers (PAP, LAM, and ILDs).
Dr. Cormac McCarthy is an Associate Professor of Medicine at the University College Dublin (UCD) and Consultant Respiratory Physician at St. Vincent’s University Hospital in Dublin, Ireland. He runs the Rare Lung Disease Referral Centre for Ireland. He is a clinician scientist with a specific interest in the pathogenesis of rare lung diseases and interstitial lung disease. Dr. McCarthy is a graduate of the Royal College of Surgeons in Ireland (RCSI), with an Honours degree in Medicine. He completed higher specialist training through the Royal College of Physician of Ireland (RCPI) and was awarded a Certificate of Satisfactory Completion of Specialist Training by the Irish Committee on Higher Specialist Training (Respiratory and General Internal Medicine). Dr. McCarthy completed a PhD in Medicine in RCSI and continued post-graduate training at the University of Cincinnati Medical Centre and Cincinnati Children’s Hospital, where he completed an ACGME-accredited Clinical Fellowship in Genetic Pulmonary Disease and continued his training there as a Rare Lung Disease Scholar.
While studying, his primary research areas were on the molecular mechanisms of lung disease, utilising pathogenesis approach to develop new therapies. He continues to have a strong interest in all lung diseases, with a particular focus on interstitial lung disease, rare lung diseases, and cystic lung disease syndromes. Dr. McCarthy has a particular interest in the molecular pathogenesis of lung disease with a specific interest in glycobiology of plasma proteins, cholesterol homeostasis in macrophages, and lipidomics in the lung. His translational research has contributed to the understanding of the pathogenesis of pulmonary alveolar proteinosis (PAP), development of novel therapeutic targets and the epidemiology of this syndrome. Additionally, his research has highlighted the use of appropriate diagnostic tests for these rare diseases and investigated the use of novel radiological analyses to monitor disease progression. His current research is investigating the role of GM-CSF in macrophage lipid homeostasis in the pathogenesis of PAP and other interstitial lung disease and identifying novel therapeutic targets for this rare disease.
Dr. Trapnell is professor of medicine and pediatrics at the University of Cincinnati, director of the Translational Pulmonary Science Center at Cincinnati Children’s Hospital Medical Center (CCHMC), co-director of the NCATS-NHLBI Rare Lung Diseases Clinical Research Consortium (RLDC), and scientific director of the Pulmonary Alveolar Proteinosis Foundation. After receiving degrees in biochemistry, genetics, and medicine, and specialty training in internal and pulmonary medicine, he first served as staff physician at the National Institutes of Health (NIH). While continuing on as senior staff physician at NIH (as a special volunteer), he established the Division of Virology and Pulmonary Studies at Genetic Therapy Inc./Novartis and served as vice president. In 1997, he moved to Cincinnati where he has maintained continuous NIH funding for a research and training program focused to the development of molecular pathogenesis-based diagnostics and therapeutics for rare lung diseases including pulmonary alveolar proteinosis (PAP), cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), lymphangioleiomyomatosis (LAM) and others. As director of the Cincinnati CF Therapeutics Development Network Center for more than a decade, he led numerous clinical trials including those resulting in FDA-approval of Creon® and Pancreaze® as therapy of CF. He also participated as co-investigator in the RLDC-based trial resulting in FDA-approval of Sirolimus® as therapy of LAM. His group helped determine the pathogenesis of autoimmune PAP, identified and developed a novel cell therapy for hereditary PAP (pulmonary macrophage transplantation), and established commercial tests for the specific diagnosis of PAP-causing diseases. Also an ardent patient advocate, Dr. Trapnell has worked closely with multiple patient foundations including those for CF, PAP, AATD, LAM, childhood interstitial lung disease, and others.